BioMarin Pharmaceuticals BMRN Other liabilities
Other liabilities at other companies
Other financials
Where this comes from
Reported directly by BioMarin Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherOperatingLiabilities.
The official record: BioMarin Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioMarin Pharmaceuticals's other liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is BioMarin Pharmaceuticals's other liabilities?
- BioMarin Pharmaceuticals (BMRN) reported other liabilities of $8.7M in Q1 2026.
- How has BioMarin Pharmaceuticals's other liabilities changed year-over-year?
- BioMarin Pharmaceuticals's other liabilities increased by 320.7% year-over-year, from $2.07M to $8.7M.
- What is the long-term trend for BioMarin Pharmaceuticals's other liabilities?
- Over 2 years (2022 to 2024), BioMarin Pharmaceuticals's other liabilities has grown at a 45.9% compound annual growth rate (CAGR), from $6.93M to $14.76M.